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Abstract
The study of a desmoglein 2 murine model of arrhythmogenic cardiomyopathy revealed cardiac inflammation as a key early 
event leading to fibrosis. Arrhythmogenic cardiomyopathy (AC) is an inherited heart muscle disorder leading to ventricular 
arrhythmias and heart failure due to abnormalities in the cardiac desmosome. We examined how loss of desmoglein 2 (Dsg2) 
in the young murine heart leads to development of AC. Apoptosis was an early cellular phenotype, and RNA sequencing 
analysis revealed early activation of inflammatory-associated pathways in Dsg2-null (Dsg2−/−) hearts at postnatal day 14 
(2 weeks) that were absent in the fibrotic heart of adult mice (10 weeks). This included upregulation of iRhom2/ADAM17 and 
its associated pro-inflammatory cytokines and receptors such as TNFα, IL6R and IL-6. Furthermore, genes linked to specific 
macrophage populations were also upregulated. This suggests cardiomyocyte stress triggers an early immune response to 
clear apoptotic cells allowing tissue remodelling later on in the fibrotic heart. Our analysis at the early disease stage suggests 
cardiac inflammation is an important response and may be one of the mechanisms responsible for AC disease progression.
Keywords Desmoglein 2 (Dsg2) · Arrhythmogenic cardiomyopathy (AC) · Desmosome · Cardiac inflammation and 
macrophages
Introduction
Arrhythmogenic cardiomyopathy (AC), also referred to as 
arrhythmogenic right ventricular cardiomyopathy (ARVC), 
is an inherited heart muscle disease characterised by ven-
tricular arrhythmias, notably ventricular tachycardia and 
fibrillation, and later in the disease process heart failure 
(Austin, et al. 2019; Sen-Chowdhry et al. 2010). It is often 
a cause of cardiac arrest in young athletes. The condition 
appears to have acute arrhythmogenic phases before a 
decline in ventricular function that occurs later in the dis-
ease. Pathologically, it is characterised by cardiac chamber 
dilatation and fibrofatty replacement of myocytes. Histori-
cally, it was thought to be a predominantly a right ventricular 
disease, but biventricular and left ventricular patterns are 
now widely recognised (Austin et al. 2019; Sen-Chowdhry 
et  al. 2010). The disease is hereditary in origin occur-
ring in about 1 in 5000 births and is generally autosomal 
dominant though recessive forms are recognised. Both may 
present with prominent extracardiac features involving the 
skin (palmoplantar keratoderma) and/or woolly hair. The 
genetic basis for the disease was first revealed by the study 
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of autosomal recessive forms of the cardiocutaneous form 
of AC and demonstrated loss-of-function mutations in 
desmoplakin (DSP) (Carvajal syndrome) and plakoglobin 
(JUP) (Naxos disease) (McKoy et al. 2000; Norgett et al. 
2000). Both of these genes encode proteins that are part of 
the desmosome. This prompted studies in autosomal domi-
nant AC including the examination of other desmosomal 
genes and revealed mutations in other components of the 
cardiac desmosome including desmoglein (DSG2), desmo-
collin2 (DSC2) and plakophilin2 (PKP2) (Syrris et al. 2007, 
2006a, b). Desmosomes tether cardiomyocytes together by 
linking cells at the intercalated disc with the intermediate 
filaments, specifically desmin, in the cytoskeleton (Vermij 
et al. 2017). Together with gap junctions and adherens junc-
tions in the area composita of the intercalated disc, they 
provide mechanical and electrical connection between cells 
(Kowalczyk and Green 2013).
AC can be a largely asymptomatic dormant condi-
tion until the initial cardiac episode occurs in later life. 
These disease triggers underlying AC are still largely 
unknown though exercise and/or infection are proposed 
external factors with desmosomal dysregulation and cell 
adhesion as likely consequences. Early observations 
from myocarditis patient biopsies previously suggested 
the involvement of a systemic viral trigger; however, 
no research has been able to confirm this as the cause 
(Calabrese et al. 2000, 2006; Campuzano et al. 2012; 
Nishikawa et al. 1999). Interestingly, subsequent stud-
ies described the presence of inflammatory infiltrates in 
postmortem biopsies from patients with AC (Campuzano 
et al. 2012). Interestingly, clinical reports of myocardi-
tis in recent paediatric cases highlight the connection 
between inflammation and AC (Martins et  al. 2018). 
Human genetic studies have been useful in identifying 
desmosomal genes that cause the disease; however, dif-
ficulties in obtaining human samples and other limita-
tions such as exposures to environmental stressors like 
exercise can vary between individuals carrying similar 
desmosomal mutations. Hence, there are now a number 
of murine models for AC; these transgenic models have 
been generated to unravel the cellular and molecular 
onset of disease progression.
One of the first murine models involved cardiac hap-
loinsufficiency of desmoplakin and recapitulated many 
of the clinical features of AC (Garcia-Gras et al. 2006). 
(Gomes et al. 2012). This was followed by the develop-
ment of other mouse models including those involved in 
the genetic manipulation of Dsg2 (Eshkind et al. 2002; 
Kant et al. 2015; Krusche et al. 2011; Pilichou et al. 2006, 
2009; Rizzo et al. 2012). The global genetic deletion of 
Dsg2 is embryonically lethal whilst heterozygotes with 
haploinsufficiency appear normal (Eshkind et al. 2002). 
In contrast, transgenic mice overexpressing a missense 
dsg2 mutation or a knock-in mouse lacking extracel-
lular EC1-EC2 adhesive domain of Dsg2 develops car-
diac dysfunction similar to that observed in AC patients 
(Krusche et al. 2011; Pilichou et al. 2009). The findings 
from Krushe et al. reported abnormal cardiac morphol-
ogy and the presence of fibrotic lesions in 2-week-old 
Dsg2 mutant mice. The Dsg2 defect caused structural 
changes where adult mice exhibited dilated cardiomyopa-
thy and compromised cardiac function. Later studies from 
the same group confirmed the presence of inflammatory 
infiltrate from 4-week-old Dsg2 mutant mice (Kant et al. 
2015). New interest in this field now supports the notion 
that inflammation does indeed shape disease pathogen-
esis in murine AC (Lubos et al. 2020). The data gathered 
from the various Dsg2 mouse models to date and our own 
study highlights the importance of cardiac inflammation 
in response to defective desmosomes and how we can use 
this knowledge to understand AC disease progression in 
humans.
Much of the recent focus is on the benefits of using phar-
macological agents to effectively target inflammatory path-
ways creating new therapies for AC (Chelko et al. 2016, 
2019). In our study, we examine the transgenic murine 
model with cardiac-specific deletion of Dsg2. The basis for 
our work was to provide further mechanistic insight into 
cardiac inflammation in the early stages of heart develop-
ment. We identify an early inflammatory response with 
unique gene expression patterns and propose key events 
that may occur in the postnatal murine heart and how these 
signatures can mould disease phenotype later on in the 
fibrotic adult heart.
Materials and methods
Generation of genetically modified mice
Animals were cared for according to the Animals (Sci-
entific Procedures) Act 1986. Mice were maintained in 
an animal core facility under UK Home Office guidelines 
related to animal welfare. Mice were kept in individually 
ventilated, pathogen-free, temperature-controlled cages 
(21–23 °C) with 12-h day/night light cycles and free access 
to standard rodent chow and water. The Dsg2 tm1c allele 
was generated at MRC Harwell (Oxfordshire, UK). Our 
study mice were generated by crossing mice expressing the 
cardiac αMHC-Cre promoter (alpha-myosin heavy chain 
promoter; Myh6) with Dsg2 floxed mice where exon 4–5 
of the desmoglein 2 gene is flanked by loxP sites. This 
mating resulted in Cre-mediated excision of desmoglein 
2 in cardiac myocytes, resulting in a frameshift mutation 
with premature truncation. Breeding pairs were set up to 
generate wild-type Dsg2+/+  (Cre−, Dsg2flx/flx) and knockout 
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Dsg2−/− mice  (Cre+, Dsg2flx/flx). Mice from both sexes 
were studied at 2, 6 and 10 weeks of age to characterise 
the histology, inflammatory and stress pathways involved 
and electrophysiological properties of the failing hearts. 
Ear samples were taken at postnatal day 13 to identify the 
genotype of the 2-week cohorts, and pups were sacrificed 
the next day for additional analyses.
In vivo assessment of cardiac function
In vivo cardiac assessment was performed with a Visual-
Sonics (VisualSonics Inc., Toronto, Canada) Vevo 3100 
high-resolution ultrasound scanner with a 30-MHz fre-
quency transducer. Mice were anaesthetised with 1.5% 
(v/v) isoflurane whilst the body temperature was main-
tained at 37 °C with a temperature probe. B- and M-mode 
parasternal long-axis and short-axis views were acquired 
to evaluate cardiovascular structures and cardiac function. 
Doppler scans were also taken to determine blood flow 
velocity and direction, as evidenced by colour differential. 
Electrocardiograms (ECGs) were also obtained with the 
built-in ECG electrode contact pads. ECG measurements 
were processed in LabChart (ADI Instruments, UK), and 
data was analysed in Prism 8.0. The Vevo LAB 3.1.1 
analysis software (VisualSonics Inc., Toronto, Canada) 
was used for quantifying the images. The most commonly 
used variables to evaluate systolic function are fractional 
shortening (FS) and ejection fraction (EF) measured 
from changes in chamber dimensions during systole (S) 
and diastole (D). Measurements and calculations were 
obtained from short-axis M mode with the left ventricle 
(LV) trace method; results were saved and processed in 
Excel before statistical analysis in Prism 8.0.
Electrophysiological mapping
We used a flexible multielectrode array (FlexMEA; Multi 
Channel Systems, Germany) to study the electrophysi-
ological properties of the intact heart as we have previ-
ously described (Aziz et al. 2018; Finlay et al. 2019). The 
data collected was used to calculate conduction velocity 
(CV), mean increase in delay (MID) and effective refrac-
tory period (ERP) from our study cohort (n = 8, both 
groups). Hearts were perfused in the Langendorff mode 
with normal oxygenated Krebs solution  (Ca2+ 1.4 mM) at 
16.5 ml/min. A unipolar silver chloride stimulation elec-
trode and a flexible 32-pole multielectrode array (MEA) 
(FlexMEA, Multielectrode System, Germany) were placed 
on the ventricular epicardium, and an  S1S2 decremental 
protocol was performed to measure the ventricular effec-
tive refractory period (VERP). A biphasic pulse of ampli-
tude 2 V and duration 0.5 ms was used for stimulation, 
with  S1S2 intervals reduced from 150 ms by decrements 
of 5 to 100 ms followed by decrements of 2 ms until tis-
sue refractoriness was reached. Arrhythmogenicity was 
further tested for by applying stimulating trains of 100 
beats at coupling intervals progressively reduced from 
100 ms. Ventricular tachycardia was defined as a ventricu-
lar arrhythmia lasting more than 2 s.
All analysis of murine electrophysiology was performed 
using custom software running in Matlab, v2014b (Math-
Works Inc., MA, USA). The time point of local activation 
was taken at the steepest negative gradient of the unipolar 
electrogram. Conduction velocities were determined using 
a gradient method, with conduction velocity defined as 
the inverse of the gradient in activation times across the 
array. Electrodes with significant noise were excluded, 
and all electrograms and time points were checked manu-
ally. MID, a well-validated measure of the inducibility of 
conduction delay, was calculated by determining the area 
under the conduction-delay curve. The mean timing of 
the activation time of all recording electrodes was used 
for each measurement of conduction delay, and the MID 
defined as the unit increase in conduction delay per unit 
reduction in  S1S2 coupling interval (ms/ms). Stimulation 
protocols were performed in normal Krebs–Henseleit 
solution (Sigma, UK).
Tissue collection and morphometric analysis
Following the ex vivo whole heart experiments, hearts 
were rinsed immediately in phosphate-buffered saline 
(PBS) before they were placed into a tissue holder and cut 
longitudinally using both right and left atrial appendages 
as a guideline. Excess moisture from both halves was blot-
ted off before the weights of the individual hearts were 
recorded. One half was fixed in 10% formalin for 24 h 
and paraffin-embedded for histology and immunostain-
ing. The other half was cut, and approximately 30 mg of 
the left ventricle was stored in RNAlater (Sigma, UK). 
Samples were obtained from 2-week- and 10-week-old 
mice for qPCR analysis (n = 5, both groups). Whole hearts 
were collected from a separate cohort of 2-week-old mice 
for fluorescence-activated cell sorting (FACS) analysis 
(n = 7, both groups).
Murine histology and immunohistochemistry
Mouse hearts collected from 2- and 10-week-old animals were 
rinsed thoroughly in PBS to remove excess blood and fixed in 
10% formalin for at least 24 h. After the fixation process, they 
were washed twice in PBS and stored in 70% ethanol before 
paraffin embedding. Paraffin-embedded myocardia were cut 
into 5-μm-thick sections and mounted on clear Plus micro-
scope slides. For histological analysis, sections were stained 
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for haematoxylin and eosin with automated Leica autostainer 
XL system (Leica Biosystems, UK) and trichrome stain kit 
(Ab150686, Abcam, UK) to detect cardiac fibrosis (according 
to the manufacturer’s instructions).
Electron microscopy
The fixed tissues from 2-week-old mice were cut into 1-mm 
pieces, post-fixed with 1% osmium tetraoxide and finally 
embedded in Araldite resin (CY212) kit. Ultrathin sections 
were post-stained with uranyl acetate and lead citrate and 
examined with a transmission electron microscope, JEM 
1230 (JEOL), at a voltage of 80 kV and a Morada (EMSIS) 
CCD camera.
DAB staining
To identify immune cell populations from 2-week 
Dsg2−/− hearts, we employed the chromogenic tissue-
staining method using the DAB detection system. The 
automated Ventana Classic and XT system (Roche Diag-
nostics, UK) was used to process our paraffin-embedded 
heart samples. The antibodies used were rat monoclonal 
CD45 (Ab25386, Abcam, UK) and rat monoclonal F4/80 
(MCA497GA Clone CI:A3-1, Serotec, UK). The OmniMap 
anti-rabbit HRP kit (760–4311, Roche Diagnostics, UK) 
was used to detect the antibodies of interest. The samples 
were counterstained with haematoxylin; slides were sealed 
with mountant and coverslip and allowed to dry. Sections 
from Dsg2+/+ and Dsg2−/− hearts were also stained with 
Dsg2 antibody (Ab150372, Abcam, UK) to confirm that 
Dsg2 had been deleted in the heart. Slides from the various 
histological stains were scanned with a Pannoramic 250 
high-throughput scanner (HistoTech, Budapest, Hungary), 
and representative images from 2-week and 10-week sam-
ples with scale bars were processed with the Panoramic 
Viewer software (HistoTech, Budapest, Hungary).
Immunofluorescent staining
Samples from paraffin-embedded 2-week- and 10-week-old 
mouse hearts were dewaxed followed by antigen retrieval 
with citrate buffer pH 6.0 (H-3300, Vector Laboratories, 
UK) for 10 min in the microwave. Slides were then rinsed 
in PBS and permeabilised with 0.25% Triton in PBS for 
15  min. Slides were washed several times in PBS and 
blocked in 5% goat serum (GS) in PBS at room temperature 
(RT) for 1 h. The samples were incubated overnight in 1% 
GS in PBS at 4 °C with the following antibodies: desmin 
(M0760, clone D33, Dako), n-cadherin (H-63) (Sc-7939, 
Santa Cruz), collagen 1 antibody Col1A1 and troponin 
T (Ab21286 and ab8295, Abcam, UK). The slides were 
washed in PBS and incubated for 1 h at RT with 2 μg/ml of 
the following secondary antibodies: 488 goat anti-mouse, 
555 donkey anti-rabbit or 555 goat anti-mouse (A-31572, 
A-11011 and A-11004, Invitrogen, UK). The samples were 
washed with PBS and counterstained with DAPI for 5 min 
before the slides were mounted a 22 mm × 50 mm coverslip 
with Immunomount (Shandon, UK). The slides were kept in 
the dark and imaged with confocal microscopy (Zeiss LSM 
710, Carl Zeiss, UK). The images were processed in ImageJ.
TUNEL staining
Paraffin samples from 2-week-old mice were stained for ter-
minal deoxynucleotidyl transferase–mediated dUTP nick-
end labelling (TUNEL) assay to confirm apoptosis caused by 
DNA fragmentation. The ApopTag® Plus In Situ Apoptosis 
Fluorescein Detection Kit (S7111 Sigma-Aldrich, UK) was 
used following the manufacturer’s instructions. The slides 
were kept in the dark and imaged with confocal microscopy 
(Zeiss LSM 880 with Airyscan Fast, Carl Zeiss, UK). The 
number of TUNEL-positive cells and total number of cell 
nuclei counterstained with DAPI were calculated in ImageJ 
with ITCN plugin (nucleus counter) to generate the % of 
TUNEL-positive cells (n = 3 both groups).
Western blotting
Heart tissue was harvested and washed with PBS. The tis-
sue was cut up and placed in lysis buffer containing T-Per 
Tissue Protein Extraction Reagent (Thermo Fisher, UK) 
and EDTA-free Complete Protease Inhibitor tablet (Roche, 
UK). The tissue was then homogenised in the lysis buffer 
using the Precellys Evolution tissue homogeniser (Bertin 
Instruments) at 0 °C for 3 × 20 s bursts. After centrifuga-
tion for 10 min at 4 °C, the supernatant containing protein 
was removed. The protein concentration was measured 
using a Bradford assay kit (Bio-Rad, UK). Equal amounts 
of protein were loaded and separated by sodium dodecyl 
sulphate–polyacrylamide gel electrophoresis (SDS-PAGE) 
(on 10% polyacrylamide gels) and transferred to a nitrocel-
lulose membrane (Whatman). The blots were incubated 
with antibodies against Dsg2, Adam17, alpha-tubulin and 
GAPDH (Ab150372, ab2051, ab2461 and ab9485, Abcam, 
UK). Blots were developed according to the manufacturer’s 
instructions (ECL Immobilon Western, Millipore).
RNA sequencing analysis
RNA samples from 2- and 10-week hearts (n = 4, both 
groups) were assessed for quantity and integrity using a 
NanoDrop 8000 V2.0 spectrophotometer (Thermo Scientific, 
USA) and Agilent 2100 Bioanalyser (Agilent Technologies, 
Waldbronn, Germany). All samples displayed low levels of 
Cell and Tissue Research 
1 3
degradation with RNA integrity numbers (RIN) between 
7.6 and 9.1. One hundred nanograms of total RNA from 
each sample was used to prepare total RNA libraries using 
the KAPA Stranded RNA-Seq Kit with RiboErase (KAPA 
Biosystems, Massachusetts, USA). Fragmentation prior to 
first-strand cDNA synthesis was carried out using incuba-
tion conditions recommended by the manufacturer for intact 
RNA samples (94 °C for 6 min), and 14 cycles of PCR were 
performed for final library amplification. Resulting librar-
ies were quantified using a Qubit 2.0 spectrophotometer 
(Life Technologies, California, USA), and the average frag-
ment size was assessed using the Agilent 2200 TapeStation 
(Agilent Technologies, Waldbronn, Germany). Equimolar 
amounts of each sample library were pooled together, and 
75-bp paired-end reads were generated for each library using 
the Illumina NextSeq® 500 high-output sequencer (Illumina 
Inc., Cambridge, UK).
In Galaxy v19.05, FASTq files were mapped to the 
GRCm38.97 mouse ensemble genome using RNAstar v2.6, 
gene and transcript counts were made with StringTie v1.3.4 
and GTF merged tables of all samples were made by String-
Tie merge v1.3.4, recounted using StringTie and differential 
expression tested by edgeR v3.24.1/Deseq2 v1.18.1. KEGG 
pathway analyses were generated using DAVID Bioinfor-
matics Resources, version 6.8 (https:// david. ncifc rf. gov/ 
home. jsp) (Huang 2009a, b). Gene lists for analysis were 
identified using a cut-off of adjusted p-value < 0.05 and 
log2 fold-change ≥ 1 and ≤  − 1. KEGG outputs were filtered 
using false discovery rate (FDR) p-value < 0.05, and data 
was log10 transformed for visualisation. Immune signatures 
were selected for the 2-week samples. The heat map was 
generated from 41 differentially expressed immune-related 
genes. An adapted version (including several macrophage-
related genes) of the ‘Mouse nCounter® Immunology Panel’ 
(nanoString) was used to filter genes, and differentially 
expressed genes were defined as adjusted p-value < 0.05, 
log2 fold-change ≥ 1.5 and ≤  − 1.5, base mean > 500. Heat 
map was plotted using the pheatmap package (v1.0.12) in 
R (v3.6.2). RNA sequencing (RNA-Seq) data are presented 
with FPKM (fragments per kilobase of transcript per million 
mapped reads) values. The data discussed in this publication 
have been deposited in NCBI’s Gene Expression Omnibus 
(Edgar et al. 2002) and are accessible through GEO Series 
accession number GSE153124 (https:// www. ncbi. nlm. nih. 
gov/ geo/ query/ acc. cgi? acc= GSE15 3124).
Quantitative real‑time PCR
Total RNA (from ~ 30 mg of tissue) was extracted from 
2- and 10-week mouse heart samples stored in RNAlater 
with the RNeasy fibrous tissue kit (74,704, Qiagen, UK). 
RNA was quantified using a NanoDrop spectrophotometer 
(Thermo Fisher Scientific, UK), and total RNA was DNase I 
treated and reverse-transcribed using a high-capacity cDNA 
reverse transcription kit (4,368,813, Applied Biosystems, 
Life Technologies, UK). Fifty nanograms of cDNA was used 
for quantitative real-time PCR (qRT-PCR), which was per-
formed using customised Taqman gene expression assays 
(Applied Biosystems, UK). Commercially available probes 
for genes of interest were used; see Table 1. Each gene was 
assayed in triplicate, and relative expression was calculated 
by using the comparative CT method normalised to GAPDH 
(n = 5 for both groups and time points). The data are pre-
sented as relative changes when compared with the control 
group (Dsg2+/+) at 2 weeks (set at one arbitrary unit).
Fluorescence‑activated cell sorting
Mice were sacrificed by neck dislocation; hearts were har-
vested and rinsed in PBS. The tissue was cut into small 
pieces and then processed in digestion buffer containing 
Hanks’ medium (10-527F, Lonza, UK), 608 U/ml of col-
lagenase I (C9891m, Sigma, UK), 187.5 U/ml collagenase 
XI (C7657, Sigma, UK), 90 U/ml hyaluronidase (H3884, 
Sigma, UK) and 90 U/ml DNAse (D4263, Sigma, UK). 
Samples were incubated at 37 °C in a shaking incubator at 
100 rpm for 1.5 h. The contents were then passed through 
70-µm cell strainers to remove debris, and the filtrate was 
diluted with PBS. These were centrifuged to create a pel-
let, and the cells were resuspended at a concentration of 
2 ×  106 cells/50  µl. Fc blocking was performed using 
TruStain FcX™ CD16/32 antibody (anti-mouse) to avoid 
non-specific binding (101,320, BioLegend, UK) accord-
ing to the supplier protocols The fluorochrome-conjugated 
antibodies used in the panel were obtained from BioLeg-
end, UK: CD11c-BV605 (117,333), CD8-AF488 (100,723), 
Ly6G-PE (127,607), F4/80-PE/Cy5 (123,111), CD11b-PE/
Cy7 (101,215), CD4-APC (100,412) and CD45.2-AF700 
Table 1  List of mouse probes used in this study. All probes were 
obtained from Thermo Fisher Scientific, UK
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(109,822). The antibodies Ly6C-eF450 (48–5932-80) and 
CD3-PerCP/eF710 (46–0032-80) were obtained from eBio-
science, UK. Fluorescence Minus One (FMO) controls were 
included for each marker. The samples were analysed using 
an LSRFortessa system (BD Biosciences, UK) equipped 
with the BD FACSDiva™ software (BD Biosciences, UK), 
followed by analysis using FlowJo (Version 10.2, Treestar, 
Ashland, OR). The CD45 + counts were normalised to the 
total number of events run; the final data show the percent-
age of the different cell types that were CD45 + .
Statistical analysis
All results are presented as mean ± SEM where n is the num-
ber of mice used. Statistical analyses were conducted using 
GraphPad Prism (version 8.0; GraphPad Software, Califor-
nia, USA). For comparison of two sets of data, a two-tailed, 
unpaired Student’s t-test was used. For the analysis of three 
or more groups, one-way ANOVA followed by Dunnett’s 
or Tukey’s multiple comparisons tests were used where 
p < 0.05 was statistically significant.
Results
Mice harbouring the tm1c allele for the Dsg2 gene (Sup-
porting Fig. 1A) were crossed with the alpha MHC Cre mice 
(Agah et al. 1997) and then bred to a second generation 
to give the study cohort:  Cre+, Dsg2flx/flx (Dsg2−/−, Dsg2 
knockout KO) or control Dsg2flx/flx (Dsg2+/+, Dsg2 wild-
type WT) mice. Newborn mice appear normal, and there are 
no striking physical differences between the adult Dsg2+/+ 
and Dsg2−/− mice; the results from morphometric analysis 
showed no differences between the two groups (unpublished 
data). We also generated a small cohort of Dsg2 heterozy-
gous mice (Dsg2+/−) to examine cardiac function and the 
effect of gene dosage in comparison to human AC disease 
development (Pilichou et al. 2006). We show desmoglein 2 
was deleted in the heart in this novel cardiac-specific mouse 
line. DAB staining, RNA-Seq, qPCR and Western blot anal-
ysis confirmed substantial decreases in transcripts translated 
into protein for Dsg2 (Supporting Fig. 1B, C).
Adult  Dsg2−/− hearts exhibit fibrosis, whereas adult 
 Dsg2+/+ and  Dsg2+/− hearts appear morphologically 
similar
We examined the heart in this murine model for signs of 
AC by comparing three groups: Dsg2 WT (Dsg2+/+), het-
erozygous HET (Dsg2+/−) and knockout KO (Dsg2−/−) 
mice at 10 weeks (Fig. 1). The morphological analysis 
of the separated hearts shows different phenotypes (a–c). 
No abnormal morphological changes or fibrotic lesions 
were observed in Dsg2+/+ (n = 31) (a) and Dsg2+/− hearts 
(n = 19) (b), whereas the Dsg2−/− hearts displayed distinct 
white fibrotic lesions (c). These epicardial lesions of vary-
ing sizes were present on the left, right or sometimes both 
ventricles in all adult Dsg2-deficient mice (n = 30). Further 
pathological examination of dissected hearts showed ~ 50% 
of Dsg2−/− hearts also had similar lesions within the intra-
ventricular septum or apex. Anatomically, dilation of the 
LV was visible in the majority of subjects (90%) with a 
small proportion of individuals exhibiting a dilated right 
ventricle or enlarged atria (15%). The degree of LV cardi-
odilation in the Dsg2−/− heart is evident in the short-axis 
mode (Supporting Fig. 1D). Most cardiac Dsg2−/− mice 
died within 6 months. Histological analysis with haema-
toxylin and eosin (H&E) and Masson’s trichrome stain 
revealed gross cardiac pathological differences between 
Dsg2+/+ (d, g and j) and Dsg2−/− hearts (f, i and l). The 
Dsg2−/− example shown in c shows epicardial and subepi-
cardial fibrosis (arrows) with similar lesional areas within 
the septum. The morphological changes observed in the 
Dsg2−/− heart is consistent with replacement fibrosis. Other 
distinct histological features include collagen deposits and 
in severe cases calcification (~ 50% of the Dsg2-deficient 
mice), which appear as dark purple aggregates (i) in 
advanced lesions as reported by earlier studies (Kant et al. 
2015). Additional histological examples of 10-week-old 
Dsg2−/− hearts are shown in Supporting Fig. 2. Example 
1 shows extensive epicardial to midwall fibrosis of the left 
ventricle with patchy epicardial fibrosis of the right ven-
tricle. Occasional lesions are present in the septum and 
subendocardium. Example 2 shows biventricular epicardial 
fibrosis with areas of transmural fibrosis. A subendocardial 
lesion is present in the left ventricle.
We measured cardiac function in younger juvenile 
mice at 6 weeks and took measurements 4 weeks later in 
adult mice (m and n). The echocardiographic parameters 
from the three genotypes are shown in Table 2 (Dsg2+/+, 
Dsg2+/− n = 8 and Dsg2−/− n = 7). The heterozygous 
group was also included in the analysis to reveal if the 
decline in cardiac function is related to gene dosage. At 
6 weeks of age, there are no statistically significant dif-
ferences in cardiac function between all groups; however, 
one Dsg2−/− mouse died between the two time points. The 
severe morphological changes in the diseased heart at 
10 weeks resulted in a substantial decline in EF (m) and 
in FS (n) when compared to the control Dsg2+/+ group, 
indicating functional impairment of contractility. The time 
course and relative decline for cardiac function is shown 
in Supporting Fig. 3A; the Dsg2−/− mice worsen with age 
where EF and FS significantly decrease by 33% and 39% 
respectively. Features such as LV dilation observed in 
Dsg2−/− hearts are comparable to those found in other Dsg2 
mouse models (Chelko et al. 2016; Krusche et al. 2011).
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We examined the electrophysiological properties 
of the heart using ECG traces from cardiac echocar-
diographic assessments acquired at 10 weeks. The ECG 
parameters of interest were compared between Dsg2+/+ 
and Dsg2−/− cohorts. Heart rates were normal (beats per 
minute (BPM) and RR interval). There were no differences 
Fig. 1  Histological and cardiac assessment of cardiac-specific desmo-
glein 2 mouse model. The Dsg2−/− adult mouse exhibits severe car-
diac dysfunction due to gross morphological defects. (a–l) Detailed 
histology of whole hearts at 10 weeks with zoomed-in areas on the 
epicardial surface using H&E and Masson’s trichrome stain in wild-
type (WT) Dsg2+/+ (a, d, g and j), heterozygous (HET) Dsg2+/− (b, 
e, h and k) and knockout (KO) Dsg2−/− (c, f, i, l) hearts. The Dsg2+/+ 
(a) and Dsg2+/− (b) hearts visually appear normal. However, the 
extreme phenotype in the Dsg2−/− heart (c) shows the myocardium 
with white fibrous plaques. These plaques have extensive calcinosis, 
which appears as purple deposits (f, i). These areas also stain posi-
tive (blue) for collagen (l). Scale bar in g–l represents 50 µm. Abbre-
viations on Dsg2−/− heart (f) are as follows: LV, left ventricle; RV, 
right ventricle; LA; left atrium; RA, right atrium; and IVS, intraven-
tricular septum. (m, n) Cardiac assessments of this mouse model 
showed ejection fraction (m) and fractional shortening (n) were sig-
nificantly reduced between Dsg2+/+ and Dsg2−/− hearts by 10 weeks 
(Dsg2+/+ and Dsg2+/− n = 8 and Dsg2−/− n = 7). There is also a sig-
nificant decline in cardiac function in Dsg2−/− heart in mice from 6 
to 10  weeks. All graphs represent mean ± SEM. ***p < 0.001 and 
****p < 0.0001
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with PR interval, P wave duration and QRS interval; 
however, there was a significant increase in QT and QTc 
intervals, in the Dsg2−/− mice (Supporting Fig. 3B). We 
further investigated the electrophysiological substrate 
in Langendorff-perfused isolated hearts using FlexMEA 
array as previously described (Aziz et al. 2018; Finlay 
et al. 2019).  S1S2 decremental protocols were performed, 
and conduction velocity; mean increase in delay, a sensitive 
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measure of conduction delay; and effective refractory 
period were measured. Capture was, however, inconsistent 
and challenging with Dsg2−/− hearts, as the fibrotic plaques 
were difficult to avoid; however, there were no significant 
changes in these parameters (Supporting Fig. 3C).
Loss of cardiac Dsg2 at 2 weeks present with signs 
of inflammation
Our studies at 10 weeks show a highly fibrotic and failing 
heart. The question arises as to what are the initial disease 
processes that promote this pathological state. To address 
this, we characterised mice histologically at 2 weeks of age 
in Fig. 2a–h. The majority of morphological observations 
from 2-week Dsg2−/− hearts (b) showed distinctive small 
surface lesions (n = 15). There were no abnormal areas 
in 2-week Dsg2+/+ hearts (a) (n = 17). The lesions in the 
Dsg2−/− cohort were located on the left and right epicardial 
surfaces although a large number (~ 50% of cases) were also 
located within the intraventricular septum. No lesions were 
observed at the apex. Detailed histological analysis revealed 
the lesions contained densely packed nuclei (d and f); these 
are absent in the Dsg2+/+ heart (c and e). These pronounced 
areas of cellular infiltrates (black arrow) surrounded by 
existing cardiomyocytes (blue arrow) in the H&E (d) and 
Masson’s trichrome stain (f) suggest inflammation may be 
an early event in the lesional areas of Dsg2-deficient hearts. 
The electron micrographs of normal myocardium show light 
and dark bands (contracted muscle) with mitochondria uni-
formly distributed along the myofibril in a healthy individ-
ual (g). However, in the Dsg2−/− heart, there is myocardial 
disarray with signs of muscle degeneration and abnormal 
mitochondria (h). The electron-dense mitochondria suggest 
mitochondrial swelling. Examples of other distinctive ultra-
structures observed in the 2-week Dsg2−/− hearts are shown 
in Supporting Fig. 4. Distorted muscle fibres are a promi-
nent feature; muscle deterioration is visible at the interca-
lated disc (A). Swollen and translucent mitochondria are 
observed throughout the Dsg2−/− heart; mitochondria with 
atypical cristae and darker outer membranes are also pre-
sent (B). There are also swollen mitochondria with myelin 
bodies and few mitochondria with empty matrixes within 
the distorted muscle compatible with necrosis and apoptosis 
(C). D shows a series of images to highlight the histological 
changes within the lesional area. These images suggest the 
myocardium is replaced by infiltrating fibroblasts and tissue 
macrophages with secretory granules.
The comparison with the pathology in the 10-week 
Dsg2−/− hearts (i and j) showed the plaque-like lesions were 
larger and compliant with fibrosis. Immunohistochemistry 
with an antibody against collagen type 1 confirmed exten-
sive fibrosis in the 10-week Dsg2−/− heart (k). Desmin is 
a muscle-specific intermediate filament protein expressed 
in cardiac, smooth muscle and skeletal muscle. Desmin 
co-staining showed dysregulation of desmin in stressed or 
damaged cardiomyocytes that were adjacent to these fibrous 
plaques in the 10-week Dsg2−/− heart (m). At higher magni-
fications in healthy myocardium (n), desmin is located at the 
intercalated disc (N-cadherin co-staining). There was little 
or no collagen type 1 detected in the 2-week Dsg2−/− heart 
(l). Desmin localises at the Z-discs as the intercalated discs 
were not visible in our sample (o).
Comparison of cardiac gene expression at 2 
and 10 weeks
We next performed and compared bulk RNA-Seq data 
from 2- and 10-week-old murine heart tissue to identify 
potential pathways involved in the early pathogenesis of 
this disease (Fig. 3). There were a number of significantly 
differentially expressed genes at 2 weeks when compared 
to the 10-week dataset (a) with some overlap of common 
genes between the postnatal and adult periods (a′). The 
top 15 differentially expressed genes in 2- and 10-week 
mice are displayed in Tables 3 and 4. The top 15 genes 
in the 2-week Dsg2−/− hearts were largely linked to the 
immune response including Cd180, Card11, Trem2 and 
Mpeg1. KEGG pathway analysis between the two time 
points further indicated that the pathways upregulated at 
2 weeks particularly were linked to inflammatory path-
ways including Janus kinases (JAKs), signal transducer 
and activator of transcription proteins (STATs), growth 
factors and pro-inflammatory cytokines such as inter-
leukin 6 (IL-6) (b). In contrast, KEGG pathway analysis 
Fig. 2  Gross morphological changes are evident in Dsg2−/− hearts at 
2 weeks of age. Histological analysis confirms early signs of inflam-
mation. (a–h) Detailed analysis of Dsg2+/+ and Dsg2−/− hearts with 
H&E, Masson’s trichrome stain and electron microscopy. (a) The 
myocardium in Dsg2+/+ heart appears normal with no abnormal mor-
phology (c, e). The H&E analysis for the postnatal Dsg2−/− heart (b, 
d) presents extreme phenotype and inflammation with the accumula-
tion of dense nuclei, predominantly immune cells (black arrow) and 
some normal cardiomyocytes (blue arrow). (f) The 2-week Dsg2−/− 
hearts do not stain positive for collagen, but there are clear changes 
within the myocardium. Scale bars represent 50  µm (c–f). (g, h) 
Electron micrographs show examples of Dsg2+/+ (g) and Dsg2−/− (h) 
hearts. The Dsg2−/− sample shows distorted muscle fibres and elec-
tron-dense mitochondria, suggesting signs of mitochondrial swelling. 
Scale bars represent 2000 µm (g and h). Gross morphological com-
parison of the adult (i) and postnatal Dsg2−/− (j) hearts. Large dense 
fibrous plaques are present in the adult heart where changes in the 
extracellular matrix have already taken place, whereas inflammation 
is the proposed key event in the postnatal heart. (k–o) Immunohis-
tological analysis reveals collagen deposition is present in the adult 
Dsg2−/− heart (k, m, n) but not detected in the 2-week Dsg2−/− heart 
(l, o). Desmin is located at the intercalated disc (n) when co-stained 
with n-cadherin in healthy myocardium whilst the lesional area (m) 
shows dysregulation of desmin in the adult Dsg2−/− heart. Scale bars 
represent 100 µm (k and l) and 10 µm (m, n, o)
◂
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at 10 weeks revealed upregulated pathways linked to 
changes in extracellular matrix and tissue remodelling 
(focal adhesion and cell adhesion molecules). The dataset 
also shows that inflammatory pathways (NF-kappa B sig-
nalling and cytokine-cytokine receptor) were also active 
at 10 weeks (Supporting Fig. 5A). It has been well docu-
mented that fibrosis is evident in other adult Dsg2 mouse 
models (Chelko et al. 2016; Kant et al. 2015; Pilichou 
et al. 2009). To explore whether fibrotic pathways were 
altered at 2 weeks in Dsg2−/− hearts, the expression of 
several fibrosis-associated genes was assessed. Col1a1, 
Col3a1 and Ctgf were significantly upregulated at 
2 weeks in Dsg2−/− hearts, although Tgfβ2 did not change 
in the early stages of the disease (Supporting Fig. 5B). 
The real-time PCR data is supported by the findings in 
Table 3; among the top 15 differentially expressed genes 
in 2-week Dsg2−/− hearts include fibrosis-related genes 
such as Timp1 (tissue inhibitor of metalloproteinases). 
In the adult Dsg2−/−heart, Cola1 and Col3A1 expression 
both declined by 10 weeks, Ctgf was highly expressed 
at both time points whilst Tgfβ2 increased significantly 
in the adult Dsg2−/− heart (Supporting Fig. 5B). Inter-
estingly, timp-1 is also highly expressed in the adult 
Dsg2−/− heart (Table 3).
Histological, immunohistochemical and RNA-Seq data 
suggests the presence of inflammatory infiltrate in 2-week 
Dsg2−/− hearts. Therefore, a heat map was generated from 41 
differentially expressed immune-related genes (c). One gene of 
interest included a significant increase in the inflammatory cell 
marker CD45 (Ptprc), and further analysis of the transcriptome 
data revealed that the main population cells within the lesion 
appeared to be predominately macrophages. Upregulated genes 
associated with activated and mature macrophages Adgre1 (or 
its common name F4/80), Mpeg1, Fcgr1 and Cd68 (d, d′, d′′ 
and d′′′). Mpeg1 is also listed as one of the top 15 genes in the 
2-week dataset (Table 3). Cells of monocyte lineage express 
CD68, a protein highly expressed by monocytic phagocytes, 
macrophages and osteoclasts. This gene is also expressed by 
circulating and tissue macrophages. Toll-like receptor protein 
2 (Tlr2 or Cd282) and Tlr9 (Cd289) both recognise foreign 
material and can initiate any innate immune activation pattern 
including a macrophage-mediated response (d′′′′ and d′′′′′). 
The data in Table 5 lists additional M1 and M2 macrophage 
markers, cytokines and factors that are also upregulated in the 
2-week Dsg2−/− RNA-Seq dataset. Our data show both M1 
and M2 genes are upregulated. We were also able to identify 
mouse-specific M2 cell surface markers such as Fizz1, Ym1/2 
and Arg1 (Raes et al. 2002). We acknowledge that the M1/M2 
paradigm of macrophage polarisation is a complex process and 
gene expression profiles will vary in different cardiac diseases 
or injury models (Nahrendorf and Swirski 2016). It is evident 
that distinct pathways are activated in the Dsg2-null postna-
tal and adult hearts. Collectively, our findings show that the 
processes of inflammation and fibrosis are interconnected and 
Table 2  Echocardiographic assessments of Dsg+/+ (WT), Dsg2+/− (HET) and Dsg2−/− (KO) mice at 6 weeks and 10 weeks of age
Dsg2+/+ and Dsg2+/− (n = 8) and Dsg2−/− (n = 7). Data are presented as the mean ± SEM. Parameters with significant differences have been high-
lighted in bold. Please refer to Fig. 1 and Supplementary Fig. 2A. Cardiac function significantly declines with age in the Dsg2−/− group ( From 6 
to 10 weeks): Ϯ *** p < 0.001 for both EF and FS. There are also significant differences between Dsg2+/+ (WT) and Dsg2−/− (KO) groups:  α 
**** p < 0.0001 for EF. β  *** p < 0.001 for FS.    γ * p < 0.05 for LVAW; d and LVID; s. ¥  ** p < 0.01 for IVS; d 
HR heart rate, CO cardiac output, EF ejection fraction, FS fractional shortening, LV mass left ventricular mass, IVS interventricular septum, 
LVAW left ventricle anterior wall, LVID left ventricle interior diameter, LVPW left ventricle posterior wall, d diastole, s systole
Parameter Dsg+/+ Dsg+/− Dsg2−/− Dsg+/+ Dsg+/− Dsg2−/−
6 weeks 10 weeks
HR BPM 504 ± 14.5 515 ± 16 536 ± 20 498 ± 13.3 502 ± 19 516 ± 12
CO ml/min 14.8 ± 1.5 13.85 ± 2.1 15.54 ± 1.73 14.9 ± 2 15.9 ± 2 11.67 ± 1.82
EF % 68 ± 2.23 63.41 ± 3.16 62.47 ± 2.86 Ϯ 63.7 ± 2.6 α 58.8 ± 3.25 43.62 ± 2.18 Ϯ α
FS % 37.18 ± 1.61 34 + 2.25 33.27 ± 2.05 Ϯ 34.14 ± 1.88 β 30.8 ± 2.16 21.28 ± 1.83 Ϯ β
LV mass mg 82.76 ± 10.1 80.63 ± 8.47 90.67 ± 11.1 106.2 ± 9.6 100.3 ± 13.8 114 ± 9.76
IVS, d mm 0.69 ± 0.06 0.68 ± 0.05 0.63 ± 0.07 0.85 ± 0.05 ¥ 0.73 ± 0.05 0.65 ± 0.03 ¥
IVS, s mm 1.02 ± 0.08 0.94 ± 0.06 0.93 ± 0.12 1.06 ± 0.09 1.05 ± 0.08 0.84 ± 0.06
LVAW, d mm 0.74 ± 0.07 0.75 ± 0.05 0.73 ± 0.08 0.8 ± 0.06 0.76 ± 0.04 0.72 ± 0.04
LVAW, s mm 1.17 ± 0.07 1.13 ± 0.06 1.08 ± 0.11 1.16 ± 0.06 γ 1.07 ± 0.07 0.93 ± 0.05 γ
LVID, d mm 3.28 ± 0.13 3.32 ± 0.13 3.42 ± 0.12 3.34 ± 0.15 3.59 ± 0.18 3.73 ± 0.18
LVID, s mm 2.2 ± 0.14 2.35 ± 0.16 2.31 ± 0.16 2.36 ± 0.14 γ 2.63 ± 0.22 2.94 ± 0.17 γ
LVPW, d mm 0.77 ± 0.03 0.81 ± 0.06 0.86 ± 0.07 1.02 ± 0.08 0.82 ± 0.06 0.95 ± 0.06
LVPW, s mm 1.08 ± 0.04 1.03 ± 0.04 1.21 ± 0.1 1.24 ± 0.08 1.08 ± 0.05 1.26 ± 0.1
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Fig. 3  RNA-Seq reveals specific immune cell populations such as 
macrophages are upregulated in Dsg2−/− hearts at 2  weeks of age. 
(a) Bar plot depicting the number of differentially expressed genes, 
both upregulated and downregulated, between Dsg2+/+ and Dsg2−/− 
mice at 2 and 10  weeks (Dsg2+/+ and Dsg2−/− n = 4, for both time 
points). (a′) The Venn diagram represents the number of differen-
tially expressed genes between Dsg2+/+ and Dsg2−/− groups at the 
two time points and the number of genes which cross over between 
both groups. (b) KEGG pathway analyses for upregulated genes 
at 2  weeks. (c) A heat map was generated from 41 differentially 
expressed immune-related genes. Red for high expression, yellow for 
medium and blue for low expression of genes. (d–d′′′′′) Transcrip-
tome data (FPKM = fragments per kilobase of transcript per mil-
lion mapped reads) show macrophages are the main inflammatory 
cell population present in Dsg2−/− hearts. Genes of interest include 
Adgre1 (F480) and Mpeg1 (d, d′), both highly expressed in mature 
macrophages. Fcgr1 and Cd68 (d′′, d′′′) are both expressed in mono-
cytes and macrophages, and Tlr2 and Tlr9 (d′′′′, d′′′′′) trigger the 
innate immune response. Graphs represent mean ± SEM. *p < 0.05, 
**p < 0.01, ***p < 0.001 and ****p < 0.0001 
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further investigation into this relationship would unravel the 
complex phases of murine AC disease progression.
The inflammatory infiltrate observed at 2 weeks 
consists of macrophages
To further characterise the cellular infiltrate observed 
in the lesional areas, DAB chromogenic staining for 
inf lammatory cells with CD45 and F4/80 for mac-
rophages was performed (Fig. 4). Dsg2+/+ hearts showed 
no inflammatory cells within the myocardium with the 
majority located within the blood vessel (a and a′′). How-
ever, in the myocardium of cardiac-specific Dsg2−/− mice, 
there was an increase in inflammatory cell marker CD45 
staining in the lesional areas (previously described in 
Fig. 2), particularly within the epicardial surface and 
Fig. 4  Inflammation and cells from the innate immune response 
play an important role in the early stages (2  weeks) of desmoglein 
2 murine AC disease progression. (a–a′′′′′) DAB immunostaining 
analysis in 2-week-old Dsg2+/+ (a, a′′, a′′′′) and Dsg2−/− (a′, a′′′, 
a′′′′′) hearts. All scale bars represent 50 µm (a–a′′′′′). The zoomed-in 
areas for each heart show the same region where we have stained for 
CD45 (a′′, a′′′) and F4/80 (a′′′′, a′′′′′). There are no immune cells 
present within the myocardium of the Dsg2+/+ heart (a′′); however, 
a large population of CD45 + cells are present in the large vessels 
of the heart. The Dsg2−/− heart (a′′′) shows increased expression of 
CD45 + cells on the epicardial surface and within the intraventricu-
lar septum region. The selected areas of interest show the pres-
ence of macrophages (a′′′′′). (b, b′) To validate the CD45 + DAB 
results, qRT-PCR (b) and RNA-Seq (b′) confirmed the presence 
of CD45 + cells (Ptprc) in Dsg2−/− hearts at 2  weeks of age when 
compared to their Dsg2+/+ littermates. These results confirm that 
this unique CD45 + signature is only observed in Dsg2−/− postna-
tal hearts. (c–c′′′) Transcriptome data to confirm the activation and 
recruitment of macrophages in 2-week-old Dsg2−/− hearts. Ccl2 (c′, 
c′′′) and its receptor Ccr2 (c, c′′) were both highly expressed during 
this inflammatory stage. All data represent mean ± SEM. *p < 0.05 
and ****p < 0.0001
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intraventricular septum (a′ and a′′′). The DAB staining 
also confirmed the presence of macrophages (F4/80) in 
the Dsg2−/− heart (a′′′′′), but these were absent in the lit-
termate control (a′′′′). The increase in CD45 + cells in 
2-week-old Dsg2−/− hearts when compared to adult hearts 
(10 weeks) was confirmed by RT-PCR (b) and RNA-Seq 
analyses (b′). Increased expression of chemokine mono-
cyte chemotactic protein MCP-1 (Ccl2) and its receptor 
C–C motif chemokine receptor 2 (Ccr2) in the 2-week 
Dsg2−/− heart suggests macrophage recruitment is initi-
ated during early cardiac development to clear damaged/
stressed cardiomyocytes (c, c′, c′′ and c′′′) (Mosser and 
Edwards 2008).
To shed more insight into these results, we examined 
the inflammatory infiltrate observed at 2 weeks with FACS 
analysis (Fig. 5). Specific gating strategies were employed to 
isolate and identify the immune cell population from whole 
hearts (a–g). Cells were isolated with CD45, CD11b and 
F4/80 antibodies (n = 7, both groups). There was a signifi-
cant increase in CD45 + cells in the Dsg2−/− heart (a and b) 
when compared to their littermate controls and a specifically 
large CD11b-positive population (c and d) that includes cells 
of the innate immune response such as neutrophils, mono-
cytes, granulocytes and macrophages. Earlier transcriptome 
analysis suggested the presence of macrophages in the young 
diseased heart we gated with F4/80, which confirmed that a 
high proportion of these CD45 + cells were macrophages (e 
and f). To examine whether a T cell population was within 
the CD45 + cells, CD3, CD4 and CD8 antibodies were used, 
which revealed a relatively low number of T cells isolated 
from both groups (h and i).
Investigation of cardiac cell death
To assess cell death in 2-week-old Dsg2−/− hearts, 
TUNEL was used to quantify apoptosis rates (Fig. 6). 
The results showed higher apoptosis rates in the 
Dsg2−/− group at 8% compared to 0.47% in the Dsg2+/+ 
group (a, a′, a′′, a′′′, a′′′′, a′′′′′ and b). The RNA-Seq 
analysis revealed mitochondrial apoptosis-inducing fac-
tor 1 (Aifm1), which activates chromatin condensation 
and DNA fragmentation, and caspase 3, a crucial medi-
ator of apoptosis, both upregulated in the 2-week-old 
Dsg2−/− heart (c and c′′). Immunohistochemistry showed 
few cardiomyocytes (assessed by troponin T positivity) 
in the lesional areas of the Dsg2−/− heart, suggesting that 
cardiomyocytes are surrounded by macrophages (packed 
nuclei), most likely linked to phagocytosis (d, d′ and d′′). 
Numerous attempts were made with commercial kits to 
quantify necrosis in freshly isolated cardiomyocytes 
from Dsg2−/− hearts. However, due to the proximity of 
the fibrotic areas and smaller sized hearts from these 
younger animals, isolating sufficient intact cardiomyo-
cytes for this assay proved challenging. We recognise 
that this is a limitation of our study. However, electron 
micrograph analysis from 2-week Dsg2−/− murine hearts 
exhibit swollen mitochondria, crista disarrangement and 
empty mitochondria/vacuoles consistent with apoptosis 
and necrosis (Supporting Fig. 4). These results suggest 
that loss of Dsg2 causes cardiac stress and a combina-
tion of cardiomyocytes, dying macrophages and cardiac 
interstitial cells undergo apoptosis around the lesions to 
facilitate disease progression.
Table 3  Top 15 differentially expressed RNA at 2  weeks. Filtering 
criteria: log2 fold change ≥ 3 or log2 fold change ≤  − 3 and adjusted 
p-value < 0.01
Gene name (2 weeks) Log2 fold change Adjusted p-value
Cd180 3.01740 8.07E − 26
Timp1 3.03955 1.30E − 18
Card11 3.07831 7.62E − 37
Ctss 3.15527 9.79E − 73
Cyp4f18 3.16365 2.83E − 34
Clec4e 3.18540 3.01E − 19
Trem2 3.19016 5.53E − 49
Ly9 3.20628 1.11E − 25
Cd300lb 3.22897 5.46E − 32
Slfn1 3.23281 8.70E − 23
B430306N03Rik 3.29441 7.14E − 24
Gpr35 3.29686 3.31E − 27
Mpeg1 3.38740 2.85E − 53
Adam8 3.48284 1.70E − 37
Serpina3n 3.53029 1.59E − 45
Table 4  Top 15 differentially expressed RNA at 10 weeks. Filtering 
criteria: log2 fold change ≥ 3 or log2 fold change ≤  − 3 and adjusted 
p-value < 0.01
Gene name (2 weeks) Log2 fold change Adjusted p-value
Aldob  −2.9868 2.19E − 17
Clcn1  −2.5873 1.19E − 21
Nmrk2 2.0114 1.54E − 14
Ptn 2.0874 6.78E − 12
Fmod 2.0901 3.28E − 19
Angptl7 2.0949 3.10E − 13
Frzb 2.1017 5.77E − 26
P4ha3 2.1726 7.33E − 11
Crlf1 2.2238 1.79E − 12
1500015O10Rik 2.2685 1.38E − 14
Serpinb1c 2.3312 1.51E − 10
Nox4 2.3493 8.68E − 22
Slamf7 2.4634 3.07E − 23
Timp1 2.4924 4.90E − 27
Col8a2 2.4998 6.99E − 21
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iRhom2/ADAM17 activation in the 2‑week  Dsg2−/− 
heart
One pathway of interest upregulated in the 2-week 
Dsg2−/− mouse is the iRhom2/ADAM17 stress pathway 
(Fig.  7). KEGG pathway analysis initially showed the 
TNF signalling pathway was upregulated in the 2-week 
Dsg2−/− cohort. On closer inspection, RNA-Seq revealed 
the cytokine tumour necrosis factor alpha (Tnfα) was sig-
nificantly elevated at 2 weeks in the Dsg2−/− mouse heart 
(a). TNFα is cleaved from the cell surface by ADAM17 
(or TNFα-converting enzyme, TACE), an ectodomain 
sheddase enzyme. Mature Adam17 promotes the specific 
cleavage of a number of other ligands such as Il-6r and 
Dsg2. Western blot analysis revealed elevated levels of 
mature Adam17 in 2-week-old Dsg2−/− heart, indicat-
ing increased sheddase activity (b and c). RT-qPCR and 
RNA-Seq showed increased levels of Rhbdf2 (d and e) and 
Adam17 (f and g) in the 2-week-old Dsg2−/− heart. Rhbdf2 
encodes the inactive Rhomboid 2 (iRhom2) that regulates 
and promotes the maturation of ADAM17 (Adrain et al. 
2012; McIlwain et  al. 2012). The increase in Il-6, the 
ligand for Il-6r, was also identified by qRT-PCR, and RNA-
Seq showed increased IL6r (h and i). Il-6 may be released 
Fig. 5  The unique inflammatory signature observed in the Dsg2−/− 
postnatal heart contains a large macrophage population. (a–g) Exam-
ple plots of the gating strategies used to identify macrophages with 
CD45 (a, b), CD11b (c, d) and F4/80 (e, f) antibodies in 2-week-old 
Dsg2+/+ and Dsg2−/− hearts. The FMO control is shown in (g). The 
Dsg2-null heart contains a large population of CD45 + cells that are 
predominately macrophages (b, d, f). (h, i) Detailed FACS analysis 
of CD45 + cell population at 2 weeks in Dsg2+/+ and Dsg2−/− hearts. 
Bar graphs show the distribution of CD45 + cells; cells were either 
CD3 + T cells populations (h) or CD3 − macrophage or granulocyte 
population (i). There is a large macrophage population in Dsg2−/− 
hearts when compared to their littermate controls. Data represent 
mean ± SEM. ****p < 0.0001
Cell and Tissue Research 
1 3
directly from macrophages and/or stressed cardiomyocytes, 
facilitating changes in the myocardium from a physiologi-
cal to pathological state.
Discussion
To summarise our findings, the inflammatory response and 
secretion of pro-inflammatory cytokines we identified may 
play an important role in generating the phenotype in the des-
moglein 2 cardiac-specific mouse model of AC. Macrophage 
recruitment and activation follow and are accompanied by 
the activation of the fibrotic pathways, eventually leading 
to a scarred poorly functional ventricle (Fig. 8). Transcrip-
tome data and cellular phenotyping suggest key genes that 
may drive the inflammatory process and profibrotic cascade 
which lead to severe cardiomyopathy. The data support early 
inflammatory gene expression at 2 weeks followed by a more 
fibrotic picture later at 10 weeks. These multiple sequential 
events are likely to mould the disease phenotype caused by 
loss of desmoglein 2. We were able to demonstrate conse-
quent apoptosis which includes but is not exclusive to myo-
cytes. However, there were technical issues with assays for 
necrosis though it was likely to be present. Previously, the 
cardiac-specific N271S-dsg2 mouse model also showed 
inflammatory infiltrates in the myocardium of 2–3-week-old 
mice and found both necrosis and apoptosis occurred in the 
early stages of cardiac development (Pilichou et al. 2009).
The potential role of inflammation as a potential disease 
driver rather than a bystander activated as an epiphenomenon 
is only beginning to be appreciated (Austin et al. 2019; 
Chelko et al. 2019). In agreement with our study, a recent 
report has also shown that inflammation does shape the 
pathogenesis of murine AC (Lubos et al. 2020). The pres-
ence of inflammatory cell infiltration in human AC cases 
has been known for some time (Basso et al. 1996), but it 
was uncertain whether these inflammatory events lead to 
disease pathogenesis or are an epiphenomenon due to car-
diomyocyte injury. Interestingly, cardiac inflammation was 
present in 60–80% of AC. Later studies also described signs 
of distinct inflammatory infiltrates in postmortem biopsies 
from patients diagnosed with AC (Campuzano et al. 2012). 
Interestingly, six AC paediatric patients were recently iden-
tified with specific desmosomal mutations (Martins et al. 
2018). Cardiac magnetic resonance imaging confirmed myo-
cardial inflammation, and these inflammatory events were 
correlated with severe reduced biventricular cardiac func-
tion (Martins et al. 2018; Patrianakos et al. 2012). There are 
phenotypic similarities in these young patients with lesions 
present in our 2-week Dsg2−/− mouse hearts. The viral trig-
ger was not responsible for myocarditis-like episodes, but 
half of the cases were exercise induced. These ‘hot phases’ 
are often associated with a rise in troponin levels and cardiac 
inflammation. It is widely accepted that the AC phenotype 
may be worsened by stressors such as exercise and the clini-
cal course can be punctuated by acute arrhythmic episodes 
(Sen-Chowdhry et al. 2010). Inflammatory genes may also 
be considered as potential markers in the early stages of 
disease management in AC families. The recent examina-
tion of 42 human AC probands showed the association of 
circulating autoantibodies against cardiac and intercalated 
disc proteins with AC disease development (Caforio et al. 
2020). Studies in human and boxer dogs showed anti-DSG2 
autoantibodies were identified as a specific marker of AC 
(Chatterjee et al. 2018; Koga et al. 2013). This will be an 
interesting area for future work in murine models.
The early immune response at 2 weeks in Dsg2−/− mice 
was characterised by substantial macrophage infiltration 
including increased expression of genes associated with pro-
inflammatory M1 macrophages (Chávez-Galán et al. 2015; 
Liu et al. 2014). M1 activated macrophages secrete pro-
inflammatory cytokines such as IL-1, IL-6 and TNFα, and 
these and related components in the pathways were increased 
in expression in our data. In addition to this, stressed car-
diomyocytes can release TNFα to trigger the inflammatory 
process and activate the immune cell population to clear 
dying cells via apoptosis or necrosis (Dobaczewski et al. 
2011). The increased expression of genes such as Ccl2 and 
Ccr2 emphasises the important role of tissue macrophages in 
damaged Dsg2−/− hearts. These genes are active during the 
innate immune response that controls the migration and infil-
tration of monocytes/macrophages. However, it is important 
to note that the M1/M2 paradigm is increasingly challenged 
Table 5  Phenotype and function of M1 and M2 macrophage subsets 
identified with our transcriptome dataset (2 weeks versus 10 weeks). 
The table lists a range of macrophage genes that were significantly 
upregulated in the Dsg2−/− mouse heart at 2 weeks
Abbreviations for upregulated genes in the table: Ccl chemokine 
(C–C motif) ligand, CD cluster of differentiation, Ifn-γ interferon-
gamma, Il interleukin, MHC major histocompatibility complex, Tlr 
Toll-like receptor, Tnf-α tumour necrosis factor alpha, Tgf-β trans-
forming growth factor beta. Mouse-specific genes: Ym1/2 chitinase 
3-like 3, Fizz1 resistin-like molecule α1, Arg arginase
Macrophage subtype
M1 M2
Inducer Ifnγ Tgfβ1, Il6, Il-1R
Cell marker Cd86, Tlr2, Tl4 Tlr1, Tlr8, Cd163, Cd206
Mouse only: Fizz1, Ym1/2, Arg1
Cytokine Tnfα, Il-6, Il1R Tgfβ1, Il-6
Chemokine Ccl2, Ccl3, Ccl4, 
Ccl5, Ccl8, Ccl9, 
Ccl11
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as expression profiles can vary in different disease models 
(Nahrendorf and Swirski 2016). Several genes that are indica-
tive of an M2 macrophage phenotype (and, consequently, type 
2 immunity) were upregulated in our bulk RNA-sequencing 
dataset in 2-week Dsg2−/− hearts. The early inflammatory pro-
cess is also accompanied by the upregulation of the iRhom2/
Adam17 stress pathway and its downstream targets such as 
Il-6. We observed an increase in Il-6R and Tnfα in 2-week 
Dsg2−/− hearts with RNA-Seq and RT-PCR; the cytokine pro-
file suggested the role of Adam17 sheddase activity. Mature 
Adam17 was only detected in the Dsg2−/− hearts.
We originally gathered information from our cardiac-
specific desmoglein 2 mouse model by first comparing 
the echocardiographic and histological data in the Dsg2 
heterozygous knockout mouse (Dsg2+/−) with control 
(Dsg2+/+) and knockout (Dsg2−/−) cohorts. The decline 
in cardiac function seen in the homozygotes was compa-
rable to that seen in other models (Krusche et al. 2011; 
Pilichou et  al.  2009). The Dsg2+/− cohorts would be 
equivalent to human studies as AC patients have het-
erozygous mutations for DSG2. The histological analysis 
revealed Dsg2 haploinsufficiency did not cause inflam-
mation or display distinct fibrous lesions in 10-week-old 
Dsg2+/− hearts in the absence of additional provocation. 
Interestingly, echocardiographic analysis revealed these 
mice do exhibit a slight decrease in cardiac function, 
Fig. 6  Apoptosis and inflammation occur simultaneously in the 
diseased postnatal heart. (a–a′′′′′) TUNEL analysis in 2-week-old 
Dsg2+/+ (a–a′′) and Dsg2−/− (a′′′–a′′′′′) hearts; scale bar represents 
50 µm. (b) Bar graph to show there is a higher TUNEL index in the 
Dsg2−/− hearts when compared to their control littermates. (c, c′) 
RNA-Seq analysis reveals the mitochondrial genes apoptosis-inducing 
factor 1 Aif1m (c) and caspase 3 Casp3 (c′) were both upregulated at 
2  weeks, suggesting nuclear disassembly during apoptosis. All data 
represent mean ± SEM. **p < 0.01, ***p < 0.001 and ****p < 0.0001. 
(d–d′′) Immunohistochemistry of two different lesional areas in 
2-week-old Dsg2−/− heart. These examples show the dominance of 
the inflammatory infiltrate (d′) and evidence of myocardial disarray 
(d′′). Scale bar represents 50 µm (d′, d′′)
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though not significant when compared to their wild-type 
littermates. In humans, a number of disease-causing hete-
rozygous mutations in DSG2 are missense mutations and 
may have a dominant negative effect on the assembling 
desmosome. It is important to note that DSG2 mutations 
in humans are often more pathogenic in the heterozy-
gous state when triggers such as exercise and stress are 
involved.
Fig. 7  Transcriptome data reveals early activation of stress and 
inflammatory-associated pathways in 2-week-old Dsg2−/− hearts 
when compared to 10-week-old adult cohort. (a) The cytokine 
Tnfα is highly expressed at this early stage of development. (b, c) 
The iRhom2/ADAM17 pathway is upregulated in the 2-week-old 
Dsg2−/− heart. Western blotting of lysates from adult and postnatal 
mouse heart with GAPDH as loading control. Densitometric analy-
sis reveals increased mature ADAM17 (~ 93 kDa) in the 2-week-old 
Dsg2−/− heart (b). Each positive band was normalised to GAPDH and 
quantified by NIH ImageJ (c). Data represent results from a single 
experiment. (d–i) Quantitative PCR analysis and RNA-Seq confirm 
the activation of Rhbdf2 (d, e) and Adam17 (f, g) at this early time 
point. Pro-inflammatory cytokine IL-6 (h) is also highly expressed at 
this stage; IL-6R (i), a substrate of Adam17, was also detected with 
RNA-Seq data. All bar graphs represent mean ± SEM. *p < 0.05, 
**p < 0.01, ***p < 0.001 and ****p < 0.0001 
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It is known that the heart contains a resident popula-
tion of macrophages, and it is thought, that as in other 
tissues, they have a housekeeping function detecting 
potential myocardial injury and clearing cellular waste 
(Heidt et al. 2014). In addition, they may also have novel 
roles such as such as influencing excitability in the atri-
oventricular node (Hulsmans et al. 2017). The modest 
electrophysiological phenotype observed in this model is 
also indicative that arrhythmia may predominantly arise 
from fibrosis and scar formation rather than pronounced 
changes in conduction as seen with desmoplakin muta-
tions (Gomes et al. 2012). The best characterised injury 
model is that of myocardial infarction, and there is a 
carefully sequenced process of acute innate inflammation 
driven largely by macrophages, which ultimately results 
in repair and scar formation (Swirski and Nahrendorf 
2018) (Frodermann and Nahrendorf 2018; Nahrendorf 
2018). Whilst there are some similarities, there are also 
differences. In our case, the two processes of inflamma-
tion and repair seem to occur simultaneously but largely 
terminate at 10 weeks. It is unclear if this is due to exten-
sive myocardial damage or whether desmosomal disrup-
tion early in life as the heart matures postnatally is the 
critical driver.
Our observation that inflammation is most active early on 
suggests that intervention with immune-suppressing drugs 
should be given before extensive fibrosis sets in. IL-6 is 
implicated in chronic inflammation and cancer and is one 
potential therapeutic target for intervention (López-Mejías 
and González-Gay 2019). Glycogen synthase kinase-3 beta 
(GSK-β), a key player in the pathogenesis of AC, can also 
regulate the inflammatory response (Chelko et al. 2016). In 
addition, the success of small molecule inhibition of nuclear 
factor kappa B signalling implicates inflammatory processes 
(Chelko et al. 2019). Secondly, any clinical immune signature 
may be detected prior to overt disease onset and there may be 
Fig. 8  Summary of the proposed key events in cardiac-specific 
murine model of AC. The loss of desmoglein 2 can trigger cell death 
and initiate the immune response. Postnatal Dsg2−/− hearts (2 weeks) 
suggest inflammation occurs excessively in response to desmosome 
dysfunction. Our findings reveal key genes are upregulated during the 
early innate immune response. Pro-fibrotic genes are also expressed 
at this postnatal period resulting in the pathological condition 
observed in Dsg2−/− adult mice. (This figure was created with tem-
plates from Servier Medical Art, licensed under a Creative Common 
Attribution 3.0 Generic License. http:// smart. servi er. com)
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benefits of therapeutic intervention at this early stage. Future 
studies in murine models of AC could explore further the use 
of known inhibitors of inflammation and fibrosis.
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